YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect

Polo-like kinase 4 (PLK4) is indispensable for precise control of centriole duplication. Abnormal expression of PLK4 has been reported in many human cancers, and inhibition of PLK4 activity results in their mitotic arrest and apoptosis. Therefore, PLK4 may be a valid therapeutic target for antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Qian, Xiong, Lu, Xia, Yong, Feng, Zhanzhan, Gao, Tiantao, Wei, Wei, Song, Xuejiao, Ye, Tinghong, Wang, Ningyu, Peng, Cuiting, Li, Zhongping, Liu, Zhihao, Yu, Luoting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194023/
https://www.ncbi.nlm.nih.gov/pubmed/30337519
http://dx.doi.org/10.1038/s41419-018-1071-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194023/
https://www.ncbi.nlm.nih.gov/pubmed/30337519
http://dx.doi.org/10.1038/s41419-018-1071-2

Ejemplares similares